• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients.

作者信息

Andriani M, Nordio M, Saporiti E

机构信息

Nephrology and Dialysis Unit, Ospedale Civile, Dolo, Venice, Italy.

出版信息

Nephron. 1996;72(2):218-24. doi: 10.1159/000188845.

DOI:10.1159/000188845
PMID:8684530
Abstract

We investigated the best time of administration of desferrioxamine (DFO) with respect to the dialysis session, using the approach of the stochastic dynamic system, integrated with the classical pharmacokinetic models. In the 6 patients studied, the mean arrival times of DFO, aluminoxamine (AlO) and ferrioxamine (FO) were, respectively, 193, 1,350 and 126 min, the mean residence times were 1,048, infinite, 1,190 min, respectively. AlO serum levels reach steady state in a mean time of 7 h and 22 min and remain stable in the interdialytic period. FO achieves a peak at the end of DFO infusion and declines during the interdialytic period. DFO, AlO and FO persist a very long time in the body of the uremic patient, thus the dialysis session should be administered when AlO and FO reach steady state. With a dose of 5-10 mg/kg b.w. of DFO, we propose to start the dialysis 8-12 h after the infusion if the main purpose is to treat Al overload or 2-3 h after the infusion if the main purpose is the treatment of hemosiderosis.

摘要

相似文献

1
Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients.
Nephron. 1996;72(2):218-24. doi: 10.1159/000188845.
2
Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients.
Nephrol Dial Transplant. 1992;7(9):931-8. doi: 10.1093/ndt/7.9.931.
3
Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.去铁胺给药后尿毒症血清中铝去铁胺和铁去铁胺的比例较低。
Clin Chem. 1998 Jun;44(6 Pt 1):1262-8.
4
Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis.通过活性炭血液灌流和血液透析去除铝氧胺和铁氧胺。
Kidney Int. 1992 May;41(5):1400-7. doi: 10.1038/ki.1992.205.
5
Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.采用两种给药方案对急性铝中毒的血液透析患者进行低剂量(5毫克/千克)去铁胺治疗。
Nephrol Dial Transplant. 1996 Jan;11(1):125-32.
6
Kinetics of aluminoxamine and feroxamine chelates in dialysis patients.
Nephron. 1992;60(4):411-7. doi: 10.1159/000186800.
7
Pharmacokinetics of desferrioxamine and of its iron and aluminum chelates in patients on peritoneal dialysis.去铁胺及其铁和铝螯合物在腹膜透析患者中的药代动力学。
Clin Chim Acta. 1988 Apr 29;173(3):313-6. doi: 10.1016/0009-8981(88)90019-8.
8
The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients.
Ren Fail. 2001 Nov;23(6):789-95. doi: 10.1081/jdi-100108190.
9
Desferrioxamine in the treatment of aluminum overload.去铁胺治疗铝过载。
Clin Nephrol. 1985;24 Suppl 1:S94-7.
10
Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis.
Clin Chim Acta. 1987 Dec;170(2-3):331-8. doi: 10.1016/0009-8981(87)90144-6.

引用本文的文献

1
The role of chelation in the treatment of other metal poisonings.螯合在治疗其他金属中毒中的作用。
J Med Toxicol. 2013 Dec;9(4):355-69. doi: 10.1007/s13181-013-0343-6.
2
A risk-benefit assessment of iron-chelation therapy.铁螯合疗法的风险效益评估。
Drug Saf. 1997 Dec;17(6):407-21. doi: 10.2165/00002018-199717060-00006.